Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:349998rdf:typepubmed:Citationlld:pubmed
pubmed-article:349998lifeskim:mentionsumls-concept:C0021494lld:lifeskim
pubmed-article:349998lifeskim:mentionsumls-concept:C0030193lld:lifeskim
pubmed-article:349998lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:349998lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:349998lifeskim:mentionsumls-concept:C0021149lld:lifeskim
pubmed-article:349998lifeskim:mentionsumls-concept:C0524527lld:lifeskim
pubmed-article:349998pubmed:issue4lld:pubmed
pubmed-article:349998pubmed:dateCreated1978-7-15lld:pubmed
pubmed-article:349998pubmed:abstractTextI.C.I. 35868 is a promising new intravenous induction agent, but intravenous injection of the initial 2% formulation frequently caused pain. The solvent vehicle of the 2% formulation, which contained Cremophor E.L. and ethanol, was therefore investigated to see if this could be the cause of the pain. Twenty volunteers received both 5 ml isotonic saline and 5 ml solvent vehicle intravenously. The injection of saline never caused pain, but the solvent caused mild or moderate pain in 9 patients. I.C.I. 35868 was therefore reformulated in a 1% solution, excluding ethanol from the solvent. When intravenous injection of I.C.I. 35868 1% was compared to methohexitone 1% in 24 patients, both agents caused pain. Four out of 12 patients reveiving I.C.I. 35868 1% felt pain, with a total pain "score" of 6, but 6 out of 12 patients who received methohexitone 1%, felt pain, with a total pain "score" of 12. In no instance was intravenous injection followed by persistant pain, or evidence of thrombosis or phlebitis.lld:pubmed
pubmed-article:349998pubmed:languageenglld:pubmed
pubmed-article:349998pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:349998pubmed:citationSubsetIMlld:pubmed
pubmed-article:349998pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:349998pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:349998pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:349998pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:349998pubmed:statusMEDLINElld:pubmed
pubmed-article:349998pubmed:issn0001-5164lld:pubmed
pubmed-article:349998pubmed:authorpubmed-author:RollyGGlld:pubmed
pubmed-article:349998pubmed:authorpubmed-author:KayBBlld:pubmed
pubmed-article:349998pubmed:issnTypePrintlld:pubmed
pubmed-article:349998pubmed:volume28lld:pubmed
pubmed-article:349998pubmed:ownerNLMlld:pubmed
pubmed-article:349998pubmed:authorsCompleteYlld:pubmed
pubmed-article:349998pubmed:pagination317-22lld:pubmed
pubmed-article:349998pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:349998pubmed:meshHeadingpubmed-meshheading:349998-H...lld:pubmed
pubmed-article:349998pubmed:meshHeadingpubmed-meshheading:349998-I...lld:pubmed
pubmed-article:349998pubmed:meshHeadingpubmed-meshheading:349998-P...lld:pubmed
pubmed-article:349998pubmed:meshHeadingpubmed-meshheading:349998-A...lld:pubmed
pubmed-article:349998pubmed:meshHeadingpubmed-meshheading:349998-P...lld:pubmed
pubmed-article:349998pubmed:meshHeadingpubmed-meshheading:349998-A...lld:pubmed
pubmed-article:349998pubmed:meshHeadingpubmed-meshheading:349998-P...lld:pubmed
pubmed-article:349998pubmed:meshHeadingpubmed-meshheading:349998-M...lld:pubmed
pubmed-article:349998pubmed:meshHeadingpubmed-meshheading:349998-C...lld:pubmed
pubmed-article:349998pubmed:meshHeadingpubmed-meshheading:349998-D...lld:pubmed
pubmed-article:349998pubmed:year1977lld:pubmed
pubmed-article:349998pubmed:articleTitleI.C.I. 35868 - The effect of a change of formulation on the incidence of pain after intravenous injection.lld:pubmed
pubmed-article:349998pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:349998pubmed:publicationTypeClinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:349998lld:pubmed